Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lexicon Pharmaceuticals, Inc. filings document a biopharmaceutical issuer with common stock listed on The Nasdaq Capital Market under LXRX. Its regulatory record includes Form 8-K reports on operating and financial results, clinical and regulatory updates, material agreements, debt financing, equity offerings and conversions of preferred stock into common stock.
Proxy and governance filings describe director elections, executive compensation, equity incentive plans and shareholder voting matters. Registration and prospectus-related disclosures address common-stock issuance programs, capital structure and public-market financing alongside the company's development programs in cardiometabolic and neurologic disease areas.
LEXICON PHARMACEUTICALS, INC. (LXRX) insider group led by Artal entities reported an internal restructuring of their stake. Artal Participations S.a r.l. had previously acquired 408,434.70 shares of Series B convertible preferred stock at $65.00 per share. Each preferred share automatically converted into 50 shares of common stock once shareholder approval and other conditions were satisfied, which occurred on April 30, 2026. As a result, 408,434.70 preferred shares converted into 20,421,735 shares of common stock. Following the conversion, Artal Participations S.a r.l. indirectly holds 175,156,062 shares of common stock, reflecting a large, ongoing position rather than an open-market purchase or sale.
Artal Participations and related investment entities update their Schedule 13D on Lexicon Pharmaceuticals to reflect additional preferred share purchases and conversion into common stock. On February 17, 2026, Artal Participations S.a r.l. bought 41,289.58 shares of Preferred Stock at $65.00 per share under a Preferred Purchase Agreement.
Together with earlier purchases, 408,434.70 preferred shares automatically converted on April 30, 2026 into 20,421,735 shares of Lexicon common stock after charter approval conditions were met. The reporting persons collectively beneficially own 227,034,705 Lexicon common shares, or 51.1% of the 444,196,390 shares outstanding as of May 4, 2026, giving the group majority beneficial ownership.
Lexicon Pharmaceuticals reported sharply improved Q1 2026 results. Revenue rose to $21.1 million from $1.3 million, driven mainly by $20.0 million of development milestone revenue from its Novo Nordisk licensing agreement, alongside modest INPEFA net product sales of $1.1 million.
Net loss narrowed to $1.0 million, or less than $0.01 per share, compared with a $25.3 million loss a year earlier, as both research and development and selling, general and administrative expenses declined. Operating cash outflow was $14.7 million, but total cash, cash equivalents, short‑term investments and restricted cash increased to $199.7 million as of March 31, 2026, helped by approximately $96.5 million of February common and preferred stock issuances.
The company highlighted progress across its pipeline, including the SONATA‑HCM Phase 3 trial of sotagliflozin, ongoing efforts to potentially resubmit the ZYNQUISTA NDA for type 1 diabetes, Fast Track‑designated pilavapadin in diabetic peripheral neuropathic pain, and Novo Nordisk’s Phase 1 work on LX9851. Management believes current liquidity, collaborations and a new $100 million Hercules loan facility support operations for at least the next 12 months.
Lexicon Pharmaceuticals reported sharply improved results for the quarter ended March 31, 2026, with total revenues of $21.1 million, up from $1.3 million a year earlier, driven mainly by $20.0 million of milestone revenue from its Novo Nordisk license.
Research and development expenses fell to $12.8 million and selling, general and administrative expenses declined to $9.2 million, reducing the quarterly net loss to $1.0 million from $25.3 million. Net product revenue from INPEFA was $1.1 million.
Cash, investments and restricted cash rose to $199.7 million as of March 31, 2026, helped by $96.5 million of equity proceeds in February. The company also put in place a $100 million loan facility with Hercules Capital, drawing $55 million to refinance prior debt.
Lexicon highlighted progress across its pipeline, including ongoing Phase 3 SONATA-HCM enrollment for sotagliflozin, anticipated mid-2026 NDA resubmission for ZYNQUISTA in type 1 diabetes, Novo Nordisk’s Phase 1 program for obesity drug LX9851, and FDA clearance to advance pilavapadin into Phase 3 for diabetic peripheral neuropathic pain.
Lexicon Pharmaceuticals entered a new loan and security agreement with Hercules Capital providing up to $100 million in term loans maturing in May 2030. An initial $55 million tranche was funded at closing and will be used to repay Lexicon’s existing Oxford Finance loan facility.
The facility carries a floating interest rate equal to the prime rate plus 3.10%, with a floor of 9.85%, and an initial interest-only period of 18 months that can be extended up to 30 months upon achievement of specified clinical, regulatory and financial milestones. The loans are secured by a first lien on all assets and include minimum cash and revenue covenants and other customary restrictions.
In connection with the financing, Lexicon granted Hercules warrants to purchase up to 1,257,860 shares of common stock at $1.59 per share, exercisable for five years, issued in stages alongside the three loan tranches.
LEXICON PHARMACEUTICALS, INC. director Philippe Amouyal received new equity awards as part of his compensation. On May 1, 2026, he was granted 43,478 stock options to buy common stock at an exercise price of $1.61 per share, expiring on May 1, 2036.
The option vests in three equal annual installments over the first three anniversaries of the grant date. He was also granted 35,714 restricted stock units (RSUs), which vest in full on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock, with no open-market buying or selling reported in this filing.
LEXICON PHARMACEUTICALS director Christopher J. Sobecki received new equity awards as part of his compensation. On May 1, 2026, he was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share, vesting in three equal annual installments on each of the first three anniversaries of the grant date. He was also granted 35,714 restricted stock units, which vest in full on the first anniversary of the grant date, with each unit representing a contingent right to receive one share of common stock. These are awards from the company rather than open‑market purchases or sales.
LEXICON PHARMACEUTICALS director Sam L. Barker received new equity awards. On May 1, 2026, he was granted a stock option for 43,478 shares of common stock at an exercise price of $1.61 per share, vesting in three equal annual installments on each of the first three anniversaries of the grant date.
He also received 35,714 restricted stock units (RSUs), each representing one share of common stock. These RSUs vest in full on the first anniversary of the grant date, providing additional equity-based compensation tied to continued service.
Lexicon Pharmaceuticals director Ivan Cheung received new equity awards as part of his compensation. On May 1, 2026, he was granted a stock option for 43,478 shares of common stock at an exercise price of $1.61 per share, expiring on May 1, 2036. This option vests in three equal annual installments over the first three anniversaries of the grant date.
He was also granted 35,714 restricted stock units, each representing a contingent right to receive one share of common stock. These RSUs vest in full on the first anniversary of the grant date. Both awards are reported as directly owned and represent routine, compensation-related acquisitions rather than open-market purchases or sales.
LEXICON PHARMACEUTICALS director Judith L. Swain received new equity awards as part of her compensation. On May 1, 2026, she was granted stock options for 43,478 shares of common stock at an exercise price of $1.61 per share, vesting in three equal annual installments on each of the first three anniversaries of the grant date and expiring on May 1, 2036. She was also granted 35,714 restricted stock units, which vest in full on the first anniversary of the grant date. Each restricted stock unit represents a contingent right to receive one share of common stock.